Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Neuropathy (US)

Articles with lock require a subscription to GLG News | Request a free trial
August 11, 2008
CBT and neuromodulation are underutilized.
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Given the increased awareness for toxicities related to SSRIs, this article is quite important.
August 11, 2008
Byetta Preventing Mortality? Even IF True, Wrong Formulation?
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
Author: GLG Expert Contributor
The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point.  Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...
August 6, 2008
More questions than answers:
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor
 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?
Jason CampagnaJuly 2, 2008
The Pleitropic Effects of Volatile Anesthetics: Pain and Inhaled Agents?
Analysis of: Why anaesthetics can make the pain worse | www.newscientist.com
Author: Jason Campagna, Director of Clinical Quality and Analytics, Cottage Health System
There are well over 70 Million general anesthetics performed in the US each year, and the majority of these utilize one of four generally used inhaled anesthetic agents (Sevoflurane, Desflurane, Isoflurane and Halothane). How these drugs act to produce "unconsciousness" is largely unknown, but as the...
June 19, 2008
Cardiology:Do Beta Blockers Truly Harm Non-Cardiac Surgical Patients?
Analysis of: Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com
Author: GLG Expert Contributor
1.  Beta Blockers are now implicated in negative outcomes for some non-cardiac surgical patients. 2.  The POISE Trial is probably teaching us that vasoactive medications need to be utilized judiciously, given to many, but not all surgical patients. 3.  The POISE Trial results conflict...
June 19, 2008
Race to Market, with Competition Hot on Heels
Analysis of: After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 | newsroom.lilly.com
Author: GLG Expert Contributor
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
Daniel WynnJune 5, 2008
Novartis and Multiple Sclerosis: A Major Commitment
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Daniel WynnJune 2, 2008
Abbott's ABT-089 --Much More than a Treatment for ADHD
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
May 30, 2008
AGI-1067 May Address More than the Blood Sugar
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: GLG Expert Contributor
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 
Daniel WynnApril 24, 2008
COPAXONE from the START of MS
Analysis of: Teva Seeks Approval for the Extension of its Indication to Include the Treatment of Patients with a First Clinical Event Suggestive of MS | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Copaxone has become the leading treatment for relapsing remitting MS in the US.  The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.

Page : 1 2 3 4 Next1 to 10 of 33

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T01:45:15.453